Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

FDA could authorize COVID shots for children under 5 in June

The Food and Drug Administration could authorize a Covid-19 vaccine for children under age 5 in June, according to two people familiar with the plans.

The agency has asked members of its advisory panel, called the Vaccines and Related Biological Products Advisory Committee, to set aside several days in June to potentially meet, the people said.

The panel members haven’t been told what the tentative meeting will be about, but it’s presumed the discussion will involve the topic of vaccinations in the nation’s youngest cohort, one of the people said. The first potential meeting date is June 1.

The days are still subject to change, the people said, especially if the trajectory of the Covid cases continues to rise in the United States.

The FDA had also tentatively scheduled meetings of the advisory committee in May, but those were eventually scrapped.

There are an estimated 19.5 million children under age 5 in the U.S. and Puerto Rico, according to NBC News data.

Kids under 5 are the only group in the U.S. ineligible to receive a Covid vaccine, but efforts to vaccinate this age group have been met with delays.

Source: NBC News

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!